Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009

ShioShin Jean, Po Ren Hsueh, Wen-Sen Lee, Kwok Woon Yu, Chun Hsing Liao, Feng Yi Chang, Wen Chien Ko, Jiunn Jong Wu, Yen Hsu Chen, Yao Shen Chen, Jien Wei Liu, Min Chi Lu, Cheng Yi Liu, Carlos Lam, Ray-Jade Chen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To investigate the in vitro susceptibilities to various carbapenems amongst clinical Gram-negative bacteria isolated from patients in intensive care units of ten major teaching hospitals in Taiwan in 2009, a survey was conducted to determine the minimum inhibitory concentrations (MICs) of ertapenem, imipenem, meropenem and doripenem against isolates of Enterobacteriaceae (n = 594), Pseudomonas aeruginosa (n = 185), Acinetobacter baumannii (n = 192) and Burkholderia cepacia (n = 23) using the agar dilution method. Susceptibilities were determined according to 2009, 2011 and 2012 MIC breakpoints recommended by the CLSI as well as 2012 MIC breakpoints recommended by EUCAST. Based on CLSI 2012 criteria, the ertapenem susceptible rate was 93%, 81%, 68% and 92% for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, respectively. All Proteus mirabilis and Morganella morganii isolates were susceptible to ertapenem; however, 64% of P. mirabilis and all M. morganii isolates were non-susceptible to imipenem. Meropenem and doripenem had better activities than imipenem against ertapenem-non-susceptible Enterobacteriaceae isolates. E. coli, K. pneumoniae and E. cloacae with ertapenem MICs ≥ 4 mg/L were synchronously not susceptible to imipenem, meropenem and doripenem. Imipenem susceptibility was 65% and 29% for P. aeruginosa and A. baumannii, respectively. Additionally, P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 8 mg/L were also not susceptible to meropenem and doripenem. These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by ertapenem-non-susceptible Enterobacteriaceae as well as P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 4 mg/L.

Original languageEnglish
Pages (from-to)457-462
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume41
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

meropenem
Carbapenems
Imipenem
doripenem
Gram-Negative Bacteria
Taiwan
Microbial Sensitivity Tests
Intensive Care Units
Acinetobacter baumannii
Pseudomonas aeruginosa
Enterobacteriaceae
Morganella morganii
Enterobacter cloacae
Proteus mirabilis
Klebsiella pneumoniae
Escherichia coli
Burkholderia cepacia
Serratia marcescens
Teaching Hospitals
Agar

Keywords

  • Acinetobacter baumannii
  • Carbapenem
  • Clinical and Laboratory Standards Institute
  • Enterobacteriaceae
  • Non-susceptibility

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan : Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. / Jean, ShioShin; Hsueh, Po Ren; Lee, Wen-Sen; Yu, Kwok Woon; Liao, Chun Hsing; Chang, Feng Yi; Ko, Wen Chien; Wu, Jiunn Jong; Chen, Yen Hsu; Chen, Yao Shen; Liu, Jien Wei; Lu, Min Chi; Liu, Cheng Yi; Lam, Carlos; Chen, Ray-Jade.

In: International Journal of Antimicrobial Agents, Vol. 41, No. 5, 05.2013, p. 457-462.

Research output: Contribution to journalArticle

@article{29ffb4476c544a28a2e017323a9ddfb9,
title = "Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009",
abstract = "To investigate the in vitro susceptibilities to various carbapenems amongst clinical Gram-negative bacteria isolated from patients in intensive care units of ten major teaching hospitals in Taiwan in 2009, a survey was conducted to determine the minimum inhibitory concentrations (MICs) of ertapenem, imipenem, meropenem and doripenem against isolates of Enterobacteriaceae (n = 594), Pseudomonas aeruginosa (n = 185), Acinetobacter baumannii (n = 192) and Burkholderia cepacia (n = 23) using the agar dilution method. Susceptibilities were determined according to 2009, 2011 and 2012 MIC breakpoints recommended by the CLSI as well as 2012 MIC breakpoints recommended by EUCAST. Based on CLSI 2012 criteria, the ertapenem susceptible rate was 93{\%}, 81{\%}, 68{\%} and 92{\%} for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, respectively. All Proteus mirabilis and Morganella morganii isolates were susceptible to ertapenem; however, 64{\%} of P. mirabilis and all M. morganii isolates were non-susceptible to imipenem. Meropenem and doripenem had better activities than imipenem against ertapenem-non-susceptible Enterobacteriaceae isolates. E. coli, K. pneumoniae and E. cloacae with ertapenem MICs ≥ 4 mg/L were synchronously not susceptible to imipenem, meropenem and doripenem. Imipenem susceptibility was 65{\%} and 29{\%} for P. aeruginosa and A. baumannii, respectively. Additionally, P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 8 mg/L were also not susceptible to meropenem and doripenem. These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by ertapenem-non-susceptible Enterobacteriaceae as well as P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 4 mg/L.",
keywords = "Acinetobacter baumannii, Carbapenem, Clinical and Laboratory Standards Institute, Enterobacteriaceae, Non-susceptibility",
author = "ShioShin Jean and Hsueh, {Po Ren} and Wen-Sen Lee and Yu, {Kwok Woon} and Liao, {Chun Hsing} and Chang, {Feng Yi} and Ko, {Wen Chien} and Wu, {Jiunn Jong} and Chen, {Yen Hsu} and Chen, {Yao Shen} and Liu, {Jien Wei} and Lu, {Min Chi} and Liu, {Cheng Yi} and Carlos Lam and Ray-Jade Chen",
year = "2013",
month = "5",
doi = "10.1016/j.ijantimicag.2013.02.001",
language = "English",
volume = "41",
pages = "457--462",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan

T2 - Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009

AU - Jean, ShioShin

AU - Hsueh, Po Ren

AU - Lee, Wen-Sen

AU - Yu, Kwok Woon

AU - Liao, Chun Hsing

AU - Chang, Feng Yi

AU - Ko, Wen Chien

AU - Wu, Jiunn Jong

AU - Chen, Yen Hsu

AU - Chen, Yao Shen

AU - Liu, Jien Wei

AU - Lu, Min Chi

AU - Liu, Cheng Yi

AU - Lam, Carlos

AU - Chen, Ray-Jade

PY - 2013/5

Y1 - 2013/5

N2 - To investigate the in vitro susceptibilities to various carbapenems amongst clinical Gram-negative bacteria isolated from patients in intensive care units of ten major teaching hospitals in Taiwan in 2009, a survey was conducted to determine the minimum inhibitory concentrations (MICs) of ertapenem, imipenem, meropenem and doripenem against isolates of Enterobacteriaceae (n = 594), Pseudomonas aeruginosa (n = 185), Acinetobacter baumannii (n = 192) and Burkholderia cepacia (n = 23) using the agar dilution method. Susceptibilities were determined according to 2009, 2011 and 2012 MIC breakpoints recommended by the CLSI as well as 2012 MIC breakpoints recommended by EUCAST. Based on CLSI 2012 criteria, the ertapenem susceptible rate was 93%, 81%, 68% and 92% for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, respectively. All Proteus mirabilis and Morganella morganii isolates were susceptible to ertapenem; however, 64% of P. mirabilis and all M. morganii isolates were non-susceptible to imipenem. Meropenem and doripenem had better activities than imipenem against ertapenem-non-susceptible Enterobacteriaceae isolates. E. coli, K. pneumoniae and E. cloacae with ertapenem MICs ≥ 4 mg/L were synchronously not susceptible to imipenem, meropenem and doripenem. Imipenem susceptibility was 65% and 29% for P. aeruginosa and A. baumannii, respectively. Additionally, P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 8 mg/L were also not susceptible to meropenem and doripenem. These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by ertapenem-non-susceptible Enterobacteriaceae as well as P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 4 mg/L.

AB - To investigate the in vitro susceptibilities to various carbapenems amongst clinical Gram-negative bacteria isolated from patients in intensive care units of ten major teaching hospitals in Taiwan in 2009, a survey was conducted to determine the minimum inhibitory concentrations (MICs) of ertapenem, imipenem, meropenem and doripenem against isolates of Enterobacteriaceae (n = 594), Pseudomonas aeruginosa (n = 185), Acinetobacter baumannii (n = 192) and Burkholderia cepacia (n = 23) using the agar dilution method. Susceptibilities were determined according to 2009, 2011 and 2012 MIC breakpoints recommended by the CLSI as well as 2012 MIC breakpoints recommended by EUCAST. Based on CLSI 2012 criteria, the ertapenem susceptible rate was 93%, 81%, 68% and 92% for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, respectively. All Proteus mirabilis and Morganella morganii isolates were susceptible to ertapenem; however, 64% of P. mirabilis and all M. morganii isolates were non-susceptible to imipenem. Meropenem and doripenem had better activities than imipenem against ertapenem-non-susceptible Enterobacteriaceae isolates. E. coli, K. pneumoniae and E. cloacae with ertapenem MICs ≥ 4 mg/L were synchronously not susceptible to imipenem, meropenem and doripenem. Imipenem susceptibility was 65% and 29% for P. aeruginosa and A. baumannii, respectively. Additionally, P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 8 mg/L were also not susceptible to meropenem and doripenem. These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by ertapenem-non-susceptible Enterobacteriaceae as well as P. aeruginosa and A. baumannii isolates with imipenem MICs ≥ 4 mg/L.

KW - Acinetobacter baumannii

KW - Carbapenem

KW - Clinical and Laboratory Standards Institute

KW - Enterobacteriaceae

KW - Non-susceptibility

UR - http://www.scopus.com/inward/record.url?scp=84876289299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876289299&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2013.02.001

DO - 10.1016/j.ijantimicag.2013.02.001

M3 - Article

C2 - 23507415

AN - SCOPUS:84876289299

VL - 41

SP - 457

EP - 462

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 5

ER -